GSA Capital Partners LLP Has $240,000 Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

GSA Capital Partners LLP lowered its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 58.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,667 shares of the company’s stock after selling 15,134 shares during the period. GSA Capital Partners LLP’s holdings in Nurix Therapeutics were worth $240,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in NRIX. Driehaus Capital Management LLC acquired a new position in Nurix Therapeutics in the 2nd quarter valued at $26,778,000. Redmile Group LLC grew its stake in shares of Nurix Therapeutics by 37.7% in the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock valued at $65,900,000 after acquiring an additional 1,226,497 shares in the last quarter. Samlyn Capital LLC bought a new position in Nurix Therapeutics during the second quarter worth about $12,177,000. Ikarian Capital LLC acquired a new stake in Nurix Therapeutics in the 1st quarter worth about $4,410,000. Finally, Candriam S.C.A. raised its stake in Nurix Therapeutics by 30.5% in the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company’s stock worth $24,297,000 after purchasing an additional 272,136 shares in the last quarter.

Insider Transactions at Nurix Therapeutics

In other news, insider Gwenn Hansen sold 3,437 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $24.30, for a total transaction of $83,519.10. Following the completion of the sale, the insider now owns 50,670 shares of the company’s stock, valued at $1,231,281. The trade was a 6.35 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Christine Ring sold 5,760 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $22.23, for a total value of $128,044.80. Following the completion of the sale, the insider now owns 24,592 shares of the company’s stock, valued at approximately $546,680.16. The trade was a 18.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,321 shares of company stock worth $1,414,409. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Trading Down 1.4 %

Shares of NRIX opened at $22.05 on Friday. Nurix Therapeutics, Inc. has a 1-year low of $5.65 and a 1-year high of $29.56. The firm’s 50-day moving average price is $24.37 and its 200-day moving average price is $21.54. The firm has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.58 and a beta of 2.20.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The firm had revenue of $12.59 million for the quarter, compared to analysts’ expectations of $13.85 million. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on NRIX shares. Jefferies Financial Group assumed coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. UBS Group started coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price objective on the stock. Royal Bank of Canada dropped their price objective on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating for the company in a report on Monday, October 14th. HC Wainwright increased their target price on Nurix Therapeutics from $26.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $29.00 price target on shares of Nurix Therapeutics in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $29.40.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.